Treats acute myeloid leukemia (AML). ANDA 65036, held by Meitheal Pharmaceuticals. Idarubicin Hydrochloride.
As of Nov 22, 2026, ANDA 65036 (Idarubicin Hydrochloride), held by Meitheal Pharmaceuticals, was first approved by FDA on May 1, 2002, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Idarubicin Hydrochloride Injection in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 1, 2002 | Original application | Approved |
| Idarubicin Hydrochloride5MG/5ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Rx |
| Idarubicin Hydrochloride10MG/10ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Rx |
| Idarubicin Hydrochloride20MG/20ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Rx |
| Mar 27, 2023 | Supplement 34Labeling · Standard review | Approved | None posted |
| Jan 27, 2022 | Supplement 33Labeling · Standard review | Approved | None posted |
| Apr 27, 2020 | Supplement 27Labeling · Standard review | Approved | None posted |
| Apr 27, 2020 | Supplement 30Labeling · Standard review | Approved | None posted |
| Nov 22, 2011 | Supplement 19Labeling | Approved | None posted |
| May 1, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters